V I S I T
WORLD’S CLINICAL LABORATORY NEWS LEADER
Annual Meeting & Clinical Lab Expo
ISSN 1068-1760
I
N
Vol. 38 No.5 • 8-9/2021
T
Markers for Severe Dengue Identified
D
engue is the most common mosquito-borne viral disease to affect humans globally. In 2019, the World Health Organization identified dengue as one of the top 10 threats to global health, with transmission occurring in 129 countries and an estimated
E
R
N
A
T
I
DAILY CLINICAL LAB NEWS
®
O
Genomic Differences Cause Racial Disparities in Prostate Cancer
P
rostate cancer is a disease defined by the abnormal growth of cells. These abnormal cells can proliferate in an uncontrolled way and, if left untreated, form tumors which may metastasize or spread to other parts of the body. Prostate cancer (PCa) is the most common
solid organ malignancy in men, with 174,650 new diagnoses and 31,620 deaths expected in 2019 in the USA alone. Effective prognosis and personalized treatment regimens for PCa require identifying tumor-specific genomic factors and events and
Cont’d on page 10
Cont’d on page 12
Plasma ACE2 Predicts Prognosis of Hospitalized COVID-19 Patients
N
A
L
19-Protein Panel Detects Alzheimer’s
A
19-protein biomarker panel distinguished Alzheimer’s disease (AD) patients from healthy individuals with greater than 96% accuracy and differentiated among the early, intermediate, and late stages of AD while monitoring the progression of the disease. To capitalize on results obtained by studies showing the potential of blood proteins as candidate biomarkers for AD, Cont’d on page 14
Biomarkers Diagnose and Predict Acute Pancreatitis
E
A
levated baseline plasma ACE2 levels in COVID-19 patients have been found to be significantly associated with increased disease severity in COVID-19 patients, thereby expanding viral spread and disease burden.
cute pancreatitis (AP) is an inflammatory reaction caused by the activated pancreatic enzymes in the pancreas, which leads to subsequent pancreatic autodigestion, edema, hemorrhage, necrosis, and even distal organ dysfunction. Conventional biomarkers such as amylase, lipase, C-reactive protein (CRP), and leukocytes are less specific in assessing the severity
See article on page 25
Cont’d on page 27 V
I
S
I
LINKXPRESS COM
R E A D E R
Liquid Biopsy Test Accurately Detects Over 50 Types of Cancer
T
S E R V I C E
®
P O R T A L
Renew/Start your Free Subscription Access Interactive Digital Magazine Instant Online Product Information: LinkXpress codes of 1 Identify interest as you read magazine ®
on LinkXpress.com 2 toClick reach reader service portal Mark code(s) of interest on 3 LinkXpress inquiry matrix ®
If your subscription is not renewed every 12 months your Free Subscription may be automatically discontinued
C
esults from a clinical study confirmed that a noninvasive liquid biopsy-based blood test could accurately detect more than 50 types of cancer and could be used as a multi-cancer screening test among individuals at higher risk of the disease, including asymptomatic individuals aged 50 years or older.
Cont’d on page 16
IL, Inova, Biokit to Unite Under Werfen Brand Name
W
erfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand – Werfen. As part of this effort, the company has completed organizational transitions and adopted a new global
brand identity, including a new corporate logo. While IL, Inova and Biokit have been part of Werfen since 1992, 2009, and 1973, respectively, they will now be known simply as Werfen. The company has been known as Werfen outside of North America since 2014. The strategic Cont’d on page 37
INSIDE
COVID-19 Update. . . . . 4 Clinical News. . . . . . . . 10 IFCC News. . . . . . . . . . 33 Product News . . . . . 6-32 Industry News . . . . . . . 37 Events Calendar . . . . . 38
PUBLISHED IN COOPERATION WITH
International Federation of Clinical Chemistry and Laboratory Medicine
GLOBETECH >>> MEDIA <<<